Dual Time Point PET in Lymphoma
This study aims to investigate the value of dual time point PET/CT in lymphoma. Since FDG uptake is linked to glucose metabolism, PET imaging is also used to detect suspected sites for infectious and inflammatory disorders. In a clinical setting, it is a challenge to distinguish between FDG uptake in benign and malignant lesions and this gives rise to a considerable quantity of false positive results and decreased positive predictive values. Performing FDG-PET imaging sixty minutes after injection is common practice in the staging and surveillance of lymphoma but this procedure may not be optimal, especially not in settings where benign inflammatory lesions are of clinical concern.
In an attempt to find an alternative method for this discrimination, dual time point FDG-PET was introduced. This technique has shown itself to be a potentially promising method in FDG-PET imaging for distinguishing between malignant and benign lesions using SUV values. The reason for the different FDG uptake patterns between inflammatory and malignant lesions is unclear. Several factors may contribute to this phenomenon on a cellular basis. It has been shown that cancer cells exhibit increased numbers of glucose transporter and low level of glucose-6-phosphatase. Varying levels between different cancer cell types may explain the different FDG uptake curves. Because various cell types exhibit varying rates of FDG uptake we believe that kinetic investigation may prove to be of value in understanding different types of lymphoma and identifying how to perform precise imaging for staging and surveillance.
研究概览
地位
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
Odense、丹麦、5000
- 招聘中
- Odense University Hospital, Department of hematology
-
接触:
- Karen Mylam, MD
- 电话号码:0045 6441 3186
- 邮箱:karen.mylam@rsyd.dk
-
首席研究员:
- Karen Juul Mylam, MD
-
Roskilde、丹麦、4000
- 尚未招聘
- Roskilde Hospital
-
接触:
- Lars Møller Pedersen, MD
- 邮箱:lmpn@regionsjaelland.dk
-
副研究员:
- Lars Møller Pedersen, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Age>18 years
- Planned for curative treatment
Exclusion Criteria:
- Previously treatment with chemotherapy or irradiation
- Primary CNS lymphoma
- Recurrent lymphoma
- Transformation from indolent lymphoma
- Presence of diabetes mellitus, HIV, chronic inflammatory disease or infections
- Pregnancy or lactation
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
---|
Patients with suspected lymphoma.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression Free Survival
大体时间:2 years
|
To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.
|
2 years
|
Progression free survival
大体时间:3 years
|
To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.
|
3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Overall survival
大体时间:2 years, 3 years
|
To evaluate the predictive value of PET after 60min compared to PET after 180min in terms of outcome.
|
2 years, 3 years
|
其他结果措施
结果测量 |
大体时间 |
---|---|
To compare SUVmax with the expression of GLUT1, hexokinase, G6Pase in lymphoma cells
大体时间:1 day (After diagnostic biopsy)
|
1 day (After diagnostic biopsy)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.